Blog
RSS FeedPosted by Michael Wonder on 09 Oct 2024
MHRA launches 2024/25 business plan with focus on enabling access to groundbreaking new technology while optimising delivery for all who need our services
7 October 2024 - The MHRA has today launched its ambitious new business plan for 2024/25, setting out the agency’s core ...
Posted by Michael Wonder on 08 Oct 2024
Fruquintinib for patients with previously treated metastatic colorectal cancer
8 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Oct 2024
Bimekizumab for the treatment of patients with moderate to severe hidradenitis suppurativa
7 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Oct 2024
Consultation on NHS England proposals for a phased launch of obesity injection
3 October 2024 - Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation ...
Posted by Michael Wonder on 04 Oct 2024
Netarsudil mesylate with latanoprost for the treatment of patients with primary open-angle glaucoma or ocular hypertension
2 October 2024 - NiCE has published final evidence-based recommendations on the use of netarsudil mesylate with latanoprost (Roclanda) for ...
Posted by Michael Wonder on 02 Oct 2024
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, ESR1 mutation positive, HER2 negative breast cancer after at least one endocrine treatment
1 October 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 02 Oct 2024
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
1 October 2024 - Today NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of ...
Posted by Michael Wonder on 29 Sep 2024
Cabotegravir for the prevention of HIV-1 infection in adults and adolescents
26 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for ...
Posted by Michael Wonder on 22 Sep 2024
Fruquintinib approved to treat adult patients with metastatic colorectal cancer
20 September 2024 - The MHRA has today approved the new medicine fruquintinib (Fruzaqla) to treat adult patients with metastatic colorectal ...
Posted by Michael Wonder on 20 Sep 2024
Fosdenopterin hydrobromide for the treatment of patients molybdenum cofactor deficiency type A
19 September 2024 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 17 Sep 2024
Rozanolixizumab for the treatment of patients with generalised antibody positive myasthenia gravis
13 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 13 Sep 2024
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
12 December 2024 - Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the MHRA as an add-on maintenance treatment ...